The application to ovarian cancer treatment represents a particularly interesting example, since, beside the remarkable silencing of AKT—a gene activated in 36% of primary tumors, with the activation being associated with high-grade cancer and aggressive clinical behavior, protection to induced apoptosis, drug resistance and disease relapse [51]—the combined administration of the anticancer drug paclitaxel with AKT siRNA delivered using G6 TEA-core PAMAM nanovectors resulted in a synergistic therapeutic effect in vivo. The gene discussed is AKT1; the disease is ovarian carcinoma.